Xolair significantly improves itch in patients with severe form of chronic skin disease CSU, Novarti

Published: 2013-08-22 06:56:00

Updated: 2013-08-22 06:56:00

Xolar (omalizumab) was showed to be effective, safe and well tolerated in refractory refractory chronic spontaneous urticarial (CSU) patients, including those on antihistamines at up to four times the approved dose, Novartis Korea said on Tuesday.

Last month, Novartis announced its late-breaki...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK